Research Reports

Market Overview

• The Global Epigenetics Drugs & Diagnostic Technologies Market is expected to grow at a high CAGR during the forecasting period (2019-2026).
• Epigenetics is a process of changing the gene expression; it's a phenotype change without a change in genotype. The essential parts that are engaged with epigenetic interpretation are DNA methylation, histone changes, and non-coding RNA’s. Epigenetics drugs and diagnostic technologies are used in the screening of early-stage cancer and other abnormal changes in liver cells, brain cells, skin cells, and others. With the rising awareness among people and rising incidences & prevalence of oncology and non-oncology disorders, the interest for epigenetic analysis and medications is growing at a high pace and boosting the global epigenetics drugs and diagnostics technologies market.

Download free sample: https://www.datamintelligence.com/download-sample/epigenetics-drugs-diagnostic-technologies-market

Market Dynamics

• Rising prevalence of cancer and other chronic diseases along with growing geriatric population are the major factors driving the global epigenetics drugs & diagnostic technologies market. According to WHO, in 2018, there are an estimation of 18.1 million new cancer cases and 9.6 million deaths, about 1 in 6 deaths are due to cancer. Thus, growing cancer incidences are boosting the market growth.
• Also, funding’s by government organizations such as the National Cancer Institute (NCI), the International Human Epigenome Consortium (IHEC), and the National Institute of Health (NIH) to promote R&D activities is anticipated to propel the global epigenetics drugs & diagnostics market further. Further, increased attention of manufacturers towards the development of new epigenetics drugs is boosting the market growth.

Segmentation Analysis

• Based on product, the global Epigenetics Drugs & Diagnostic Technologies market is broadly segmented as oncology and non-oncology segment. Oncology application segment accounted for major market share in 2018, owing to the growing prevalence of cancer. However, over the forecast period, non-oncology application segment is expected to grow at a high pace. It is due to R&D initiatives undertaken by private institutions and biopharmaceutical companies for identification of epigenetic markers related to non-oncology disorders. Non-oncology disorders include cardiovascular, infectious, and other disorders. Epigenetic modifications have been proved to be the base of metabolic, infectious diseases, neurodegenerative, and many other non-oncology disorders. Thus, growing non-oncology disorder segment is driving the global market.

Geographical Analysis

• The global Epigenetics Drugs & Diagnostic Technologies market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America region accounted for major market share in 2018, in the global epigenetics drugs & diagnostics technologies market. Presence of government funding programs for ongoing research activities, better healthcare facilities, and continuously increasing incidences of oncology and non-oncology diseases including metabolic, infectious, cardiovascular, and other diseases.
• During the forecast period (2019-2026), the Asia Pacific region is projected to grow at a significant rate, owing to the rising disposable income, rising awareness about early diagnosis, and availability of effective treatment in emerging countries, such as India and China. Additionally, due to increasing cases of various types of cancers. Also, due to the presence of prominent players of the market, such as Eisai Pharmaceuticals and Oncolys Biopharma.

Competitive Analysis

• Significant players of the global epigenetics drugs & diagnostic technologies market are Thermo Fisher Scientific., Merck & Company Inc., Novartis International AG, Astex Pharmaceuticals Inc., Celenge, CellCentric Ltd., Celeron Therapeutics Ltd., Chroma Therapeutics Ltd., Eisai Pharmaceuticals, Epigentek Group Inc., and others. The diversified product portfolio is the major factor that is responsible for strengthening the position of these companies in the market. Also, they have been adopting key strategies, such as new product developments, acquisitions, and expansions, to increase their share in the epigenetics drugs & diagnostics market. For instance, in
• In January 2018, Thermo Fisher Scientific collaborated with Illumina, Inc. to sell Ion AmpliSeq technology to researchers who conduct scientific studies on Illumina’s next-generation sequencing (NGS) platforms.
• In August 2017, BellBrook Labs announced the launch of AptaFluor SAH Methyltransferase Assay, to help researchers in their research for breakthrough drugs targeting epigenetic pathways that drive cancer and other debilitating diseases.
• In May 2017, Merck developed alternative genome editing tool that makes CRISPR more efficient, flexible, and specific.
• In October 2015, Celgene’s VIDAZA® was approved by the European Commission(EC).
• In April 2015, Roche and Oryzon collaborated to develop and commercialize LSD1 inhibitors for oncology, and non-malignant conditions

View full report: https://www.datamintelligence.com/research-report/epigenetics-drugs-diagnostic-technologies-market

Enquiry before buying: https://www.datamintelligence.com/enquiry/epigenetics-drugs-diagnostic-technologies-market

About Us

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: info@datamintelligence.com

Tel: +1 877 441 4866

Website: www.datamintelligence.com